Cumberland Pharmaceuticals Inc.
CPIX
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $101.7M
$6.79
▲ +0.59%
P/E
-20.31
Mkt Cap
$101.7M
52-Wk Range
$1.85–$9.28
52-Week Range
$1.85 - $9.28
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 105.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Focused specialty pharmaceutical portfolio targeting hospital acute care settings with less competition
- Established commercial infrastructure and relationships with hospital systems and healthcare providers
- Diversified pipeline of clinical candidates with multiple therapeutic indications reducing development risk
- Niche market expertise in underserved therapeutic areas with high barriers to entry
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Strong growth ahead
Expansion of ifetroban clinical program across aspirin-exacerbated respiratory disease, systemic sclerosis, and interstitial lung diseases
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Strong
+15.9% over 3m
Quality
Excellent
Solid business
Dividend
High yield
22.09% yield
Smart-money signal
Who's buying CPIX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$0.20 vs -$0.13 consensus (-53.9% surprise). Revenue of $-8.8M vs $8.5M expected (-203.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-53.9%
Revenue trend · last 8Q
—
—
+38%
+10%
-9%
+31%
-22%
-181%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$9.1M
$10.4M
$11.7M
$10.8M
$8.3M
$13.7M
$9.1M
-$8.8M
Margins · last 8Q
Gross
81.8%
Operating
32.2%
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CPIX stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related